Top

Journal of Endocrinological Investigation

Published in:

01-11-2018 | Original Article

Does IGF-1 play a role in the etiopathogenesis of non-functioning adrenocortical adenoma?

Authors: C. T. Bahadir, G. C. Ecemis, H. Atmaca

Published in: Journal of Endocrinological Investigation | Issue 11/2018

Abstract

Purpose

The aim of this study was to investigate the possible association of insulin-like growth factor-1 (IGF-1) with the pathogenesis of non-functioning adrenocortical adenomas (NFAs).

Methods

This study included 50 female patients (mean age 54 years) with NFAs, 55 patients (mean age 48 years; 20 male, 35 female) with acromegaly and 38 female control subjects (mean age 58 years). Body mass index (BMI) and waist circumference (WC) of the subjects were recorded and blood samples for IGF-1 were taken. Insulin resistance was calculated using the homeostatic model assessment (HOMA) score. Since most of the acromegaly patients had been using medicine that could have effected insulin resistance, HOMA scores were calculated only in patients with NFAs and the controls. Computerized tomography or magnetic resonance imaging was taken of the acromegalics and controls to detect adrenal mass frequency.

Results

The mean age was similar among the groups. As expected, the serum IGF-1 levels were significantly higher in patients with acromegaly than in patients with NFAs and the controls (p < 0.001). Although BMI, WC, and serum IGF-1 levels were significantly higher (p < 0.001) in patients with NFAs, the HOMA scores were similar between patients with NFAs and control groups. Although none of the control subjects had adrenal masses, NFAs were detected in 14 (25%) out of 55 acromegalic patients.

Conclusions

Higher serum IGF-1 levels in patients with NFAs compared to the control group and an increased prevalence of NFAs in acromegaly patients compared to control subjects and the general population suggest an association of IGF-1 with the etiopathogenesis of NFA.

Kapoor A, Morris T, Rebello R (2011) Guidelines for the management of the incidentally discovered adrenal mass. Can Urol Assoc J 5:241–247. https://doi.org/10.5489/cuaj.11135 CrossRefPubMedPubMedCentral

Barzon L, Sonino N, Fallo F, Palu G, Boscaro M (2003) Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 149:273–285CrossRef

Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berruti A, Borasio P, Fava C, Dogliotti L, Scagliotti GV, Angeli A, Terzolo M (2006) Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 29:298–302. https://doi.org/10.1007/BF03344099 CrossRefPubMed

Peppa M, Boutati E, Koliaki C, Papaefstathiou N, Garoflos E, Economopoulos T, Hadjidakis D, Raptis SA (2010) Insulin resistance and metabolic syndrome in patients with non-functioning adrenal incidentalomas: a cause-effect relationship? Metabolism 59:1435–1441. https://doi.org/10.1530/EJE-10-0246 CrossRefPubMed

Midorikawa S, Sanada H, Hashimoto S, Suzuki T, Watanabe T (2001) The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clin Endocrinol (Oxf) 54:797–804CrossRef

Bernini G, Moretti A, Iacconi P, Miccoli P, Nami R, Lucani B, Salvetti A (2003) Anthropometric, haemodynamic, humoral and hormonal evaluation in patients with incidental adrenocortical adenomas before and after surgery. Eur J Endocrinol 148:213–219CrossRef

Mesiano S, Mellon SH, Jaffe RB (1993) Mitogenic action, regulation, and localization of insulin-like growth factors in the human fetal adrenal gland. J Clin Endocrinol Metab 76:968–976. https://doi.org/10.1210/jcem.76.4.8473412 CrossRefPubMed

Fottner Ch, Hoeflich A, Wolf E, Weber MM (2004) Role of the insulin-like growth factor system in adrenocortical growth control and carcinogenesis. Horm Metab Res 36:397–405. https://doi.org/10.1055/s-2004-814563 CrossRefPubMed

Rechler MM, Zapf J, Nissley SP, Froesch ER, Moses AC, Podskalny JM, Schilling EE, Humbel RE (1980) Interaction of insulin-like growth factors I and II and multiplication stimulating activity with receptors and serum protein carriers. Endocrinology 107:1451–1459. https://doi.org/10.1210/endo-107-5-1451 CrossRefPubMed

10.

Kasuga M, Van Obberghen E, Nissley SP, Rechler MM (1981) Demonstration of two subtypes of insulin-like growth factor receptors by affinity cross-linking. J Biol Chem 256:5305–5308PubMed

11.

Penhoat A, Rainey WE, Viard I, Saez JM (1994) Regulation of adrenal cell-differentiated functions by growth factors. Horm Res 42:39–43CrossRef

12.

Terzolo M, Pia A, Alì A, Osella G, Reimondo G, Bovio S, Daffara F, Procopio M, Paccotti P, Borretta G, Angeli A (2002) Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 87:998–1003. https://doi.org/10.1210/jcem.87.3.8277 CrossRefPubMed

13.

Chiodini I, Adda G, Scillitani A, Coletti F, Morelli V, Di Lembo S, Epaminonda P, Masserini B, Beck-Peccoz P, Orsi E, Ambrosi B, Arosio M (2007) Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. Diabetes Care 30:83–88. https://doi.org/10.2337/dc06-1267 CrossRefPubMed

14.

Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119:3189–3202. https://doi.org/10.1172/JCI39375 CrossRefPubMedPubMedCentral

15.

Pappa T, Papanastasiou L, Koutmos S, Tsiavos V, Roussaki P, Zilos A, Ragkou D, Kaltsas G, Piaditis G (2012) Pattern of adrenal morphology and function in patients with acromegaly. Eur J Clin Invest 42:275–281. https://doi.org/10.1111/j.1365-2362.2011.02580.x CrossRefPubMed

16.

Scaroni C, Selice R, Benedini S, De Menis E, Arosio M, Ronchi C, Gasperi M, Manetti L, Arnaldi G, Polenta B, Boscaro M, Albiger N, Martino E, Mantero F (2008) Adrenal morpho-functional alterations in patients with acromegaly. J Endocrinol Invest 31:602–606. https://doi.org/10.1007/BF03345609 CrossRefPubMed

17.

Ciresi A, Amato MC, Vetro C, Lo Coco R, Galluzzo A, Giordano C (2009) Adrenal morphology and function in acromegalic patients in relation to disease activity. Endocrine 36:346–354. https://doi.org/10.1007/s12020-009-9230-y CrossRefPubMed

18.

Ceccato F, Occhi G, Albiger NM, Rizzati S, Ferasin S, Trivellin G, Mantero F, Scaroni C (2011) Adrenal lesions in acromegaly: do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up. J Endocrinol Invest 34:353–360. https://doi.org/10.1007/BF03347459 CrossRefPubMed

19.

Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM (2016) Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol 175:G1–G34. https://doi.org/10.1530/EJE-16-0467 CrossRefPubMed

20.

Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care 23:57–63CrossRef

21.

Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, Ørskov H (2005) Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90:5627–5631. https://doi.org/10.1210/jc.2005-0531 CrossRefPubMed

22.

Terzolo M, Reimondo G, Gasperi M, Cozzi R, Pivonello R, Vitale G, Scillitani A, Attanasio R, Cecconi E, Daffara F, Gaia E, Martino E, Lombardi G, Angeli A, Colao A (2005) Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. J Clin Endocrinol Metab 90:84–90. https://doi.org/10.1210/jc.2004-0240 CrossRefPubMed

23.

Colao A (2008) The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf) 69:347–358. https://doi.org/10.1111/j.1365-2265.2008.03292.x CrossRef

24.

Derwahl M, Broecker M, Kraiem Z (1999) Clinical review 101: thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors. J Clin Endocrinol Metab 84:829–834. https://doi.org/10.1210/jcem.84.3.5519 CrossRefPubMed

25.

Ruchala M, Skiba A, Gurgul E, Uruski P, Wasko R, Sowinski J (2009) The occurrence of thyroid focal lesions and a need for fine needle aspiration biopsy in patients with acromegaly due to an increased risk of thyroid cancer. Neuro Endocrinol Lett 30:382–386PubMed

26.

Colao A, Marzullo P, Ferone D, Spiezia S, Cerbone G, Marinò V, Di Sarno A, Merola B, Lombardi G (1998) Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab 83:775–779CrossRef

27.

Manetti L, Bogazzi F, Brogioni S, Grasso L, Lupi I, Genovesi M, Cecconi E, Gasperi M, Martino E (2002) Submandibular salivary gland volume is increased in patients with acromegaly. Clin Endocrinol (Oxf) 57:97–100CrossRef

28.

Cohen O, Schindel B, Homburg R (1998) Uterine leiomyomata–a feature of acromegaly. Hum Reprod 13:1945–1946CrossRef

29.

Reincke M, Fasnachat M, Vath S, Mora P, Allolio B (1996) Adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocr Res 22:757–761CrossRef

30.

Shigematsu K, Niwa M, Kurihara M, Yamashita K, Kawai K, Tsuchiyama H (1989) Receptor autoradiographic localization of insulin-like growth factor-I (IGF-I) binding sites in human fetal and adult adrenal glands. Life Sci 45:383–389CrossRef

31.

Libe R, Dall’Asta C, Barbetta L, Baccarelli A, Beck-Peccoz P, Ambrosi B (2002) Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol 147:489–494CrossRef

32.

Tsagarakis S, Kokkoris P, Roboti C, Malagari C, Kaskarelis J, Vlassopoulou V, Alevizaki C, Thalassinos N (1998) The low-dose dexamethasone suppression test in patients with adrenal incidentalomas: comparisons with clinically euadrenal subjects and patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 48:627–633CrossRef

33.

Chiodini I (2011) Clinical review: diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 96:1223–1236. https://doi.org/10.1210/jc.2010-2722 CrossRefPubMed

34.

Perogamvros I, Vassiliadi DA, Karapanou O, Botoula E, Tzanela M, Tsagarakis S (2015) Biochemical and clinical benefits of unilateral adrenalectomy in patients with subclinical hypercortisolism and bilateral adrenal incidentalomas. Eur J Endocrinol 173:719–725. https://doi.org/10.1530/eje-15-0566 CrossRefPubMed

35.

Muscogiuri G, Sorice GP, Prioletta A, Mezza T, Cipolla C, Salomone E, Giaccari A, Pontecorvi A, Della Casa S (2011) The size of adrenal incidentalomas correlates with insulin resistance. Is there a cause-effect relationship? Clin Endocrinol (Oxf) 74(3):300–305. https://doi.org/10.1111/j.1365-2265.2010.03928.x CrossRef

36.

Kamio T, Shigematsu K, Kawai K, Tsuchiyama H (1991) Immunoreactivity and receptor expression of insulin like growth factor I and insulin in human adrenal tumors. An immunohistochemical study of 94 cases. Am J Pathol 138:83–91PubMedPubMedCentral

37.

Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE (1990) Effects of human growth hormone in men over 60 years old. N Eng J Med 323:1–6. https://doi.org/10.1056/NEJM199007053230101 CrossRef

38.

Yamamoto H, Kato Y (1993) Relationship between plasma insulin-like growth factor I (IGF-I) levels and body mass index (BMI) in adults. Endocr J 40:41–45CrossRef

39.

Schneider HJ, Saller B, Klotsche J, März W, Erwa W, Wittchen HU, Stalla GK (2006) Opposite associations of age-dependent insulin-like growth factor-I standard deviation scores with nutritional state in normal weight and obese subjects. Eur J Endocrinol 154:699–706. https://doi.org/10.1530/eje.1.02131 CrossRefPubMed

Title: Does IGF-1 play a role in the etiopathogenesis of non-functioning adrenocortical adenoma?
Authors: C. T. Bahadir
G. C. Ecemis
H. Atmaca
Publication date: 01-11-2018
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 11/2018
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-018-0869-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2018

Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS)

From inflammation to sexual dysfunctions: a journey through diabetes, obesity, and metabolic syndrome

Association of PON1 gene polymorphisms with polycystic ovarian syndrome risk: a meta-analysis of case–control studies

Clinicopathologic risk factors for right paraesophageal lymph node metastasis in patients with papillary thyroid carcinoma

Body composition and metabolic changes during a 520-day mission simulation to Mars

Combined BRAFV600E analysis and 99mTc-MIBI scintigraphy can be a useful diagnostic tool in differentiated thyroid cancer patients with incomplete bio-chemical response to first radioiodine therapy (RAIT): a pilot investigation

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials